Introduction
============

Laryngeal squamous cell carcinoma (LSCC) is one of the common malignancies of the upper respiratory tract that has been associated with a deterioration of the environment and an increase in the occupational stress. It was estimated that 13,360 new cases were diagnosed in 2017 in the United States, of which over 3,660 were fatal ([@ref-51]). In China, an estimated 26,400 new cases of LSCC and 14,500 cancer-related deaths also occurred in 2015 ([@ref-7]). Although patients with LSCC can be managed by surgical intervention, radiation therapy and chemotherapy, the overall five-year survival remains poor (approximately 60%) ([@ref-44]). Therefore, there is an urgent need to deeply understand the molecular mechanisms underlying LSCC carcinogenesis or progression in order to develop more effective therapeutic strategies.

Accumulating evidence has suggested that non-coding RNAs (ncRNAs) play crucial roles in the initiation and development of tumors. ncRNAs are loosely categorized into small ncRNAs and long non-coding RNAs (lncRNAs), both of which have regulatory functions in various biological processes. The well-documented small ncRNAs are microRNAs (miRNAs; ∼22 nucleotides long) that regulate gene expression by binding to complementary sequences in the 3′ untranslated region (UTR), leading to either inhibition of translation or degradation of the transcripts ([@ref-21]). Although the mechanisms remain unclear, growing evidence supports that lncRNAs could function as competing endogenous RNAs (ceRNAs) by competitively binding to miRNAs through their miRNA response elements (MRE) and subsequently regulate target RNA expression ([@ref-45]). This ceRNA mechanism has generated much interest to explain tumor development and progression in many malignancies, such as gastric cancer ([@ref-52]), thyroid carcinoma ([@ref-65]) and hepatoblastoma ([@ref-32]). Recent studies also have preliminarily revealed several underlying ceRNA regulatory interactions in LSCC. Luciferase reporter assay and Western blotting results suggested that AC026166.2-001 could act as a sponge of miR-24-3p and regulate the expression of p27 and cyclin D1 ([@ref-48]). lncRNA H19 was shown to serve as a ceRNA by sponging miR-148a-3p to upregulate the target gene DNA methyltransferase 1 ([@ref-58]). NEAT1 was also reported to regulate the expression of cyclin dependent kinase 6 through modulating miR-107 ([@ref-57]). Furthermore, a ceRNA network, including 30 genes, 21 miRNAs and 19 lncRNAs was also built based on microarray analysis of 6-paired clinical samples in LSCC ([@ref-62]). However, analysis of the lncRNA-miRNA-mRNA regulatory network of LSCC with larger sample sizes and confirmation of their clinical associations are still lacking.

In addition, DNA methylation has been identified as an important mechanism to regulate gene expression in cancer cells epigenetically, which not only regulates the expression of protein-encoding genes, but also affects miRNAs and lncRNAs. For example, hyper-methylation of the promoter region was observed to lead to a loss of expression of lncRNA maternally expressed gene 3 (MEG3). Downregulated MEG3 was insufficient to sponge miR-9 and block its inhibition effects on the expressions of E-cadherin and FOXO1, consequentially resulting in poor prognosis in patients with esophageal squamous cell carcinoma ([@ref-12]). The study of [@ref-16] also suggested lncRNA CTC-276P9.1 was hyper-methylated in esophageal squamous cell carcinoma. Over-expression of CTC-276P9.1 inhibited cancer cell proliferation and invasion *in vitro* probably by regulating epithelial-mesenchymal transition. [@ref-31] identified 761 lncRNA genes with DNA hyper-methylation in colorectal cancer using a free MethylCap-seq dataset. [@ref-8] found that the loci of three miRNAs (namely miR-199a-2, miR-124a-2 and miR-184) were linked to hyper-methylated differentially methylated regions (DMRs) in human testicular cancer. However, the DNA methylation regulatory mechanisms of miRNAs and lncRNAs have rarely been reported in LSCC.

The goal of this study was to establish an lncRNA-miRNA-mRNA ceRNA network in LSCC using larger samples and to investigate their methylation patterns. Our results may provide new clues for biologists to further understand the pathogenesis of LSCC.

Material and Methods
====================

Data source
-----------

lncRNA, miRNA, mRNA and methylation data were retrieved from Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) in January 2018 according to the following inclusion criteria: (1) lncRNA, miRNA, mRNA expression or methylation profiles; (2) laryngeal tissue samples, not blood, interstitial fluid or cells; (3) inclusion of control; (4) human samples; and (5) patients with LSCC.

Two lncRNA microarray datasets were obtained under accession number [GSE59652](GSE59652) (7 LSCC and 7 paired adjacent normal tissues) ([@ref-49]) and [GSE84957](GSE84957) (9 LSCC and 9 paired adjacent non-neoplastic tissues) ([@ref-13]). The microarray platforms of [GSE59652](GSE59652) and [GSE84957](GSE84957) were Agilent-033010 ([GPL13825](GPL13825), Arraystar Human LncRNA microarray V2.0) and Agilent-042818 ([GPL17843](GPL17843), Agilent-042818 Human lncRNA Micorarray 8_24_v2), respectively.

Two miRNA microarray datasets were collected under accession number [GSE70289](GSE70289) (12 LSCC tissues and 4 adjacent normal tissues) ([@ref-26]) and [GSE62819](GSE62819) (5 LSCC carcinoma and 5 paired adjacent non-neoplastic tissues). The microarray platforms of [GSE70289](GSE70289) and [GSE62819](GSE62819) were Agilent-031181 ([GPL15018](GPL15018), Unrestricted_Human_miRNA_V16.0_Microarray 030840) and Affymetrix Multispecies miRNA-3 Array ([GPL16384](GPL16384)), respectively.

Four mRNA microarray datasets were available under accession number [GSE51985](GSE51985) (10 LSCC and 10 paired adjacent normal tissues), [GSE84957](GSE84957) (9 LSCC and 9 paired adjacent normal tissues) ([@ref-13]), [GSE59102](GSE59102) (29 LSCC and 13 normal margin tissues) and [GSE58911](GSE58911) (15 LSCC and 15 normal tissue distant to LSCC) ([@ref-47]). The microarray platforms of [GSE51985](GSE51985), [GSE84957](GSE84957), [GSE59102](GSE59102) and [GSE58911](GSE58911) were Illumina HumanHT−12 V4.0 ([GPL10558](GPL10558)), Agilent-042818 ([GPL17843](GPL17843), Human lncRNA Micorarray 8_24_v2), Agilent-014850 ([GPL6480](GPL6480), Whole Human Genome Microarray 4x44K G4112F) and Affymetrix Human Gene 1.0 ST Array ([GPL6244](GPL6244)), respectively.

One set of DNA methylation data was acquired under accession number [GSE25093](GSE25093) ([@ref-40]; [@ref-39]) which included 213 blood and 109 tissue samples. Among the 109 tissue samples, 56 were isolated from oral, 16 from pharyngeal, and 22 from laryngeal origin, while 15 were of unclear origin. Thus, only these 22 samples from laryngeal origin (15 LSCC tissues and 7 controls) were used in our study. The microarray platform of [GSE25093](GSE25093) was Illumina HumanMethylation27 BeadChip ([GPL8490](GPL8490), HumanMethylation27_270596_v.1.2).

The mRNA and miRNA Seq-data of head and neck squamous cell carcinoma (Level 3) were also downloaded from The Cancer Genome Atlas (TCGA; <https://tcga-data.nci.nih.gov/>). After sample barcode screening, 559 were miRNA-mRNA matched samples, of which 18 were distributed in the alveolar crest, 30 in the root of the tongue, 22 in the buccal mucosa, 67 in the mouth floor, 8 in the hard palate, 9 in the laryngeal pharynx, 138 in the larynx, 3 in the lip, 38 in the oral cavity, 156 in the tongue, 10 in the oropharynx, 45 in the tonsil and 15 from an unclear location. Only the 138 samples from the larynx were used in our study.

Data preprocessing
------------------

For the data from Affy platform, the raw data in CEL. files were preprocessed using the oligo package (version 1.41.1; [@ref-6]) in R (version 3.4.1; [@ref-42]), including data transformation, missing value imputation with median, background correction with MAS method and quantile normalization.

For the data from Agilent and Illumina platforms, the raw data in TXT. files were preprocessed using the Linear Models for Microarray Data (LIMMA) package (version 3.34.0; [@ref-43]) in R, including data log2 transformation and median normalization.

The data (FPKM, fragment per kilobase per million mapped reads) from TCGA were quantile normalized using the preprocessCore package (version 1.40.0; [@ref-3]) in R.

Differential expression analysis
--------------------------------

The differentially expressed lncRNAs (DELs) and miRNAs (DEMs) between LSCC and normal controls were identified using the LIMMA method in R from their two included microarray datasets (lncRNA: [GSE59652](GSE59652) and [GSE84957](GSE84957); miRNA: gSE70289 and [GSE62819](GSE62819)). The *p*-value \<0.05 and \|logFC(fold change) \| \> 0.263 were set as the cut-off points. The overlap in the above two datasets was used for the following analysis of lncRNAs and miRNAs, respectively.

The differentially expressed genes (DEGs) between LSCC and normal controls were identified using the MetaDE.ES function in MetaDE package (version 1.0.5, <https://cran.r-project.org/web/packages/MetaDE/>) of R from its four included microarray datasets ([GSE51985](GSE51985), [GSE84957](GSE84957), [GSE59102](GSE59102) and [GSE58911](GSE58911)). The *p*-value \<0.05 and false discovery rate (FDR) \<0.05 were set as the cut-off points. The DEGs with the same expression trend (tau^2^ statistic = 0, *p*-value of Chi-square based Q-test \>0.05) in the four datasets were selected for the following analysis.

Wilcoxon signed-rank test (<http://www.bioconductor.org/help/search/index.html?q=wilcox.test/>) was used to screen the DMRs between LSCC and normal controls. *P* \< 0.05 was set as the threshold value. Human annotation data were retrieved from GENCODE Release 19 (GRCh37.p13) (<https://www.gencodegenes.org/human/release_19.html>). The sequences of miRNAs, lncRNAs and mRNAs in the corresponding platform [GPL8490](GPL8490) were blasted with the GRCh37.p13 to obtain the differentially methylated miRNAs, lncRNAs and mRNAs, which were then overlapped with the DELs, DEMs and DEGs to screen methylated-related DELs, DEMs and DEGs, respectively.

CeRNA regulatory network construction
-------------------------------------

Three reliable online databases, including miRcode (version 11; <http://www.mircode.org/>), starBase (version 2.0; <http://starbase.sysu.edu.cn/index.php>) ([@ref-29]) and DIANA-LncBase (version 2.0; <http://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?r=lncbasev2/index-predicted>) ([@ref-38]) were used to screen the interactions between lncRNAs and miRNAs. The union of these three datasets was used for the following analysis. The target genes of miRNAs that were linked to the lncRNAs were predicted using four frequently used algorithms, including TargetScan (version 7.2; <http://www.targetscan.org/vert_71/>) ([@ref-1]), miRBase (version 22; <https://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/>) ([@ref-15]), miRanda (version 1.9; <http://www.microrna.org/microrna/home.do/>) ([@ref-25]) and miRTarBase (version 7.0; <http://mirtarbase.mbc.nctu.edu.tw/php/index.php>) ([@ref-9]). The target genes predicted by at least two databases and a negative association with miRNAs were retained. The lncRNA-miRNA and miRNA-mRNA interactions were integrated to construct the ceRNA network, which was visualized using Cytoscape software (version 3.4; [@ref-46]) ([@ref-28]).

Function enrichment analysis
----------------------------

The Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool (version 6.8; <http://david.abcc.ncifcrf.gov>) ([@ref-11]) was used for Gene Ontology (GO) terms \[including molecular function (MF), biological process (BP) and cellular component (CC) categories\] and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses of genes in the ceRNA network. *P*-value \<0.05 was set as the cut-off value.

![The data analysis workflow.](peerj-07-7456-g001){#fig-1}

![Hierarchical clustering and heat map analysis.\
(A--B) heat map for differentially expressed lncRNAs identified in [GSE59652](GSE59652) (A) and [GSE84957](GSE84957) (B) datasets; (C--D), heat map for differentially expressed miRNAs identified in [GSE62819](GSE62819) (C) and [GSE70289](GSE70289) (D) datasets; (E) heat map for differentially expressed genes identified by meta-analysis of [GSE51985](GSE51985), [GSE84957](GSE84957), [GSE59102](GSE59102) and [GSE58911](GSE58911) datasets; (F) heat map for differentially methylated regions identified in the [GSE25093](GSE25093) dataset. The datasets of laryngeal squamous cell carcinoma collected from Gene Expression Omnibus database. Red, high expression (hyper-methylation); green, low expression (hypo-methylation).](peerj-07-7456-g002){#fig-2}

Clinical associations of lncRNAs, miRNAs and mRNAs in the ceRNA network
-----------------------------------------------------------------------

The expression levels of lncRNAs, miRNAs and mRNAs in the ceRNA network were downloaded from the TCGA data. Univariate Cox regression analysis was performed to screen for the prognosis-related (including overall survival, OS; and recurrence-free survival, RFS) lncRNAs, miRNAs and mRNAs using the survival package (version 2.40.1; <https://cran.r-project.org/package=survival>), which was used to construct the prognosis-related ceRNA network. The samples were divided into two groups based on the expression of each lncRNA, miRNA and mRNA: a low expression group (\<median) and a high expression (\>median) group. The Kaplan--Meier method with the log-rank test was used to estimate the difference in OS and RFS between the high and low expression groups. *P* \< 0.05 was considered statistically significant. Furthermore, multivariate Cox regression analysis was also performed using the survival package (version 2.40.1; [@ref-53]) to evaluate the prognostic independence of lncRNAs, miRNAs and mRNAs. The association of nodes in the prognosis-related ceRNA network with other clinical characteristics was also analyzed using the multiple linear regression model (<https://stat.ethz.ch/R-manual/R-patched/library/stats/html/lm.html>) in R.

Results
=======

Differential expression analysis
--------------------------------

The data analysis workflow is displayed in [Fig. 1](#fig-1){ref-type="fig"}. After data normalization ([Supplemental Information 1](#supp-1){ref-type="supplementary-material"}--[8](#supp-8){ref-type="supplementary-material"}), the DELs, DEMs and DEGs between LSCC and normal samples were screened according the stated thresholds. The results showed 306 (156 downregulated and 150 upregulated) and 396 (252 downregulated and 144 upregulated) DELs were identified in the datasets of [GSE59652](GSE59652) ([Fig. 2A](#fig-2){ref-type="fig"}) and [GSE84957](GSE84957) ([Fig. 2B](#fig-2){ref-type="fig"}) ([Supplemental Information 9](#supp-9){ref-type="supplementary-material"}), respectively. After comparison, 40 DELs were found to be shared in these two datasets, including six upregulated and 20 downregulated with the consistent expression trend ([Fig. 3A](#fig-3){ref-type="fig"}) ([Supplemental Information 9](#supp-9){ref-type="supplementary-material"}); a total of 1,307 (765 downregulated and 542 upregulated) and 491 (126 downregulated and 365 upregulated) DEMs were identified in the datasets [GSE62819](GSE62819) ([Fig. 2C](#fig-2){ref-type="fig"}) and [GSE70289](GSE70289) ([Fig. 2D](#fig-2){ref-type="fig"}), respectively ([Supplemental Information 9](#supp-9){ref-type="supplementary-material"}). After comparison, 443 DEMs were found to be common in these two datasets, among which 152 upregulated and 63 downregulated DEMs were shown to have a consistent expression trend ([Fig. 3B](#fig-3){ref-type="fig"}) ([Supplemental Information 9](#supp-9){ref-type="supplementary-material"}); 2,975 DEGs were found to display the similar expression trend in four mRNA expression profiles [GSE51985](GSE51985), [GSE84957](GSE84957), [GSE59102](GSE59102) and [GSE58911](GSE58911) ([Fig. 2E](#fig-2){ref-type="fig"}) ([Supplemental Information 9](#supp-9){ref-type="supplementary-material"}); and 4,567 DMRs were identified in the LSCC genome of [GSE25093](GSE25093) dataset, including 1616 hypomethylated and 2,951 hypermethylated ([Fig. 2F](#fig-2){ref-type="fig"}) ([Supplemental Information 9](#supp-9){ref-type="supplementary-material"}). After GENCODE annotation and blast analysis, 122 lncRNAs, but no miRNAs were found to be located in DMRs. Subsequently, the lncRNAs and mRNAs in DMRs were overlapped with their expression level data above to obtain the methylation-related DELs and DEGs. Consequently, five DELs (TMEM51-AS1, HCP5, SND1-IT1, RUSC1-AS1 and LINC00324) were screened ([Fig. 3C](#fig-3){ref-type="fig"}). Among these DELs, only the expression and methylation levels of lncRNA TMEM51-AS1 ([Figs. 3D](#fig-3){ref-type="fig"}--[3F](#fig-3){ref-type="fig"}) were opposite, indicating its expression may be regulated by methylation. These methylation-related genes were used to construct the ceRNA network.

![Overlapped genes identification.\
Venn diagram drawing to display the overlap of differentially expressed lncRNAs (A) and miRNAs (B) in different datasets of laryngeal squamous cell carcinoma collected from Gene Expression Omnibus database and their overlap with differentially methylated regions (C) to screen methylation related lncRNAs and miRNAs. The expression (D--E) and methylated (F) levels of overlapped lncRNAs are displayed in a histogram. ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01; ^∗∗∗^*p* \< 0.001. Contra-regulated: the expression trend of lncRNAs or miRNAs was different in two datasets. Upregulated or downregulated: lncRNAs or miRNAs exhibited the similar expression trend in two datasets, high or down expressed.](peerj-07-7456-g003){#fig-3}

CeRNA network construction
--------------------------

Twenty-four interaction pairs between five DELs and 14 DEMs were predicted using miRcode, starBase and DIANA-LncBase databases ([Table 1](#table-1){ref-type="table"}). The expression trends of these DELs and DEMs were opposite. Subsequently, the target genes of these 14 DEMs were predicted using four algorithms, with the resultant interaction pairs of 700 in TargetScan, 486 in miRBase, 341 in miRanda and 268 in miRTarBase. A total of 404 interaction pairs were ultimately left due to prediction by at least two databases and a negative association between them. These interaction pairs between DELs and DEMs, and between DEMs and DEGs were used to construct a ceRNA network, which contained 258 nodes (five DELs, 11 DEMs and 242 DEGs) ([Fig. 4](#fig-4){ref-type="fig"}). In this network, TMEM51-AS1 functioned as a ceRNA to regulate SNX21 (sorting nexin family member 21) and TRAPPC10 (trafficking protein particle complex 10) by sponging miR-106b; LINC00324 and RUSC1-AS1 acted as ceRNAs to regulate SPRY4 (sprouty RTK signaling antagonist 4), PAWR (pro-apoptotic WT1 regulator), MICAL2 (microtubule associated monooxygenase, calponin and LIM domain containing 2) and SLC39A14 (solute carrier family 39 member 14) by sponging miR-16; RUSC1-AS1 regulated SCG5 (SCG5 secretogranin V) and PRDM5 (PR/SET domain 5) by competitively binding to miR-10; RUSC1-AS1 also served as ceRNAs for ZFP1 (ZFP1 zinc finger protein) by binding to miR-7; HCP5 could interact with miR-143 to regulate RRM2 (ribonucleotide reductase regulatory subunit M2).

10.7717/peerj.7456/table-1

###### Interaction relationship between lncRNA and miRNAs.

![](peerj-07-7456-g007)

  **lncRNA**   **miRNA**
  ------------ --------------------------------------------------------------------------------------------------------------------------------
  HCP5         hsa-miR-10, hsa-miR-16, hsa-miR-186, hsa-miR-214, hsa-miR-7, hsa-miR-641, hsa-miR-143, hsa-miR-4770, hsa-miR-216b, hsa-miR-876
  LINC00324    hsa-miR-143, hsa-miR-16, hsa-miR-214, hsa-miR-216b, hsa-miR-4770
  RUSC1-AS1    hsa-miR-214, hsa-miR-10, hsa-miR-16, has-miR-216b, hsa-miR-7
  TMEM51-AS1   hsa-miR-106b, hsa-miR-765
  SND1-IT1     hsa-miR-708, hsa-miR-4306

![Competing endogenous RNAs (ceRNAs) interaction network of lncRNA-miRNA-mRNA in laryngeal squamous cell carcinoma.\
(A) interaction pairs among upregulated lncRNAs, downregulated miRNAs and upregulated mRNAs; (B) interaction pairs among downregulated lncRNAs, upregulated miRNAs and downregulated mRNAs. Square nodes represent lncRNAs; triangle nodes represent miRNAs; round nodes represent mRNAs. Edges represent the possible associations between lncRNAs, miRNAs and mRNAs. Red, upregulated; green, downregulated. Red line, the interaction between lncRNAs and miRNAs; greyish line, the interaction between miRNA and mRNAs.](peerj-07-7456-g004){#fig-4}

Function enrichment analysis
----------------------------

The DEGs in the ceRNA network was subjected to DAVID to predict their potential functions in LSCC. The results showed that 17 significant GO BP terms were enriched, including [GO:0042981](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0042981) ∼ regulation of apoptosis (PAWR), [GO:0015031](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0015031) ∼ protein transport (SNX21; SCG5), cell cycle (PRDM5) and [GO:0043407](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0043407) ∼ negative regulation of MAP kinase activity 4 (SPRY4). Six KEGG pathways were also enriched, including hsa05210: colorectal cancer, hsa04210:Apoptosis and hsa05205:Proteoglycans in cancer ([Table 2](#table-2){ref-type="table"}).

10.7717/peerj.7456/table-2

###### Function enrichment analysis for the genes in ceRNA network.

![](peerj-07-7456-g008)

  **Category**      **Term**                                                                                                      *P*-value   **Genes**
  ----------------- ------------------------------------------------------------------------------------------------------------- ----------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biology process   [GO:0006793](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0006793) ∼ phosphorus metabolic process                 0.00122     STK38, SLC20A1, ERBB3, NUAK1, MKNK1, ABI1, PIP5K1A, TRIB1, MAP3K3, SRPK2, MINPP1, ADAM10, STK24, MSH2, PRKCI, PKN2, PTPN12, GAK, MAP4K4, MTMR11, MAPK6, GSK3B, DYRK1A, PTPN1, MAP3K14, ERC1, IKBKB, DUSP7
                    [GO:0006796](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0006796) ∼ phosphate metabolic process                  0.00122     STK38, SLC20A1, ERBB3, NUAK1, MKNK1, ABI1, PIP5K1A, TRIB1, MAP3K3, SRPK2, MINPP1, ADAM10, STK24, MSH2, PRKCI, PKN2, PTPN12, GAK, MAP4K4, MTMR11, MAPK6, GSK3B, DYRK1A, PTPN1, MAP3K14, ERC1, IKBKB, DUSP7
                    [GO:0006468](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0006468) ∼ protein amino acid phosphorylation           0.00498     SRPK2, ADAM10, STK38, STK24, NUAK1, ERBB3, PRKCI, PKN2, MKNK1, ABI1, TRIB1, GAK, MAP4K4, MAPK6, MAP3K3, GSK3B, DYRK1A, IKBKB, ERC1, MAP3K14
                    [GO:0016310](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0016310) ∼ phosphorylation                              0.00801     SRPK2, ADAM10, STK38, ERBB3, MSH2, STK24, NUAK1, PRKCI, PKN2, MKNK1, ABI1, PIP5K1A, TRIB1, GAK, MAP4K4, MAPK6, MAP3K3, GSK3B, DYRK1A, IKBKB, ERC1, MAP3K14
                    [GO:0008104](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0008104) ∼ protein localization                         0.01176     STON2, SEC23A, XPO1, AP1M1, NUP160, PRKCI, CENPF, TMSB10, TRAM2, TAP2, GSK3B, NUP210, TAP1, PIKFYVE, SNX21, RAB23, SCG5, SUPT7L, SAR1B, RAB10, ERC1, KPNA2, KPNB1
                    [GO:0043407](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0043407) ∼ negative regulation of MAP kinase activity   0.00991     STK38, PTPN1, SPRY4, DUSP7
                    [GO:0042981](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0042981) ∼ regulation of apoptosis                      0.0165      DLC1, DPF2, IER3, ING3, SYVN1, ERBB3, MSH2, KLF10, PRKCI, AKAP13, CD70, PAWR, SOD2, TNFRSF10A, BAG4, TIAM1, GSK3B, GLO1, APBB2, IKBKB, MYC
                    [GO:0043067](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0043067) ∼ regulation of programmed cell death          0.0181      DLC1, DPF2, IER3, ING3, SYVN1, ERBB3, MSH2, KLF10, PRKCI, AKAP13, CD70, PAWR, SOD2, TNFRSF10A, BAG4, TIAM1, GSK3B, GLO1, APBB2, IKBKB, MYC
                    [GO:0015031](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0015031) ∼ protein transport                            0.0188      STON2, SEC23A, XPO1, AP1M1, NUP160, PRKCI, CENPF, TRAM2, TAP2, GSK3B, NUP210, TAP1, SNX21, RAB23, SCG5, SAR1B, RAB10, ERC1, KPNA2, KPNB1
                    [GO:0010941](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0010941) ∼ regulation of cell death                     0.0188      DLC1, DPF2, IER3, ING3, SYVN1, ERBB3, MSH2, KLF10, PRKCI, AKAP13, CD70, PAWR, SOD2, TNFRSF10A, BAG4, TIAM1, GSK3B, GLO1, APBB2, IKBKB, MYC
                    [GO:0045184](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0045184) ∼ establishment of protein localization        0.0204      STON2, SEC23A, XPO1, AP1M1, NUP160, PRKCI, CENPF, TRAM2, TAP2, GSK3B, NUP210, TAP1, SNX21, RAB23, SCG5, SAR1B, RAB10, ERC1, KPNA2, KPNB1
                    [GO:0008219](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0008219) ∼ cell death                                   0.0211      FUS, DPF2, DLC1, IER3, MICB, ERBB3, MSH2, AKAP13, RNF216, PAWR, ITPR1, SOD2, TNFRSF10A, BAG4, UNC5B, TIAM1, SIAH1, MYC, SPAST
                    [GO:0010033](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0010033) ∼ response to organic substance                0.0217      ADAM10, KAT2B, ERBB3, MSH2, KLF10, PRKCI, CALCOCO2, APPL1, TRIB1, B2M, HDAC4, PRKAR2A, SDC1, HDAC2, ADM, TAP2, CTSC, PTPN1, MYC
                    [GO:0016265](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0016265) ∼ death                                        0.0225      FUS, DPF2, DLC1, IER3, MICB, ERBB3, MSH2, AKAP13, RNF216, PAWR, ITPR1, SOD2, TNFRSF10A, BAG4, UNC5B, TIAM1, SIAH1, MYC, SPAST
                    [GO:0044265](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0044265) ∼ cellular macromolecule catabolic process     0.0228      ADAM10, SYVN1, USP1, RNH1, UBE2V2, RNF216, MYLIP, UBE2Q2, ZFP36L2, FBXW7, GMCL1, PSMD3, ZMPSTE24, SIAH1, PCYOX1, USP33, MYC, FBXO11, USP31
                    [GO:0007049](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0007049) ∼ cell cycle                                   0.0405      E2F3, KAT2B, MSH2, PAPD7, CENPF, APPL1, GAK, SASS6, MAPK6, GSK3B, PRDM5, PSMD3, ZNF318, HBP1, SIAH1, APBB2, KPNA2, MYC, SPAST
                    [GO:0009057](http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0009057) ∼ macromolecule catabolic process              0.0427      ADAM10, SYVN1, USP1, RNH1, UBE2V2, RNF216, MYLIP, UBE2Q2, ZFP36L2, FBXW7, GMCL1, PSMD3, ZMPSTE24, SIAH1, PCYOX1, USP33, MYC, FBXO11, USP31
  KEGG pathway      hsa05210:Colorectal cancer                                                                                    0.0377      MSH2, GSK3B, APPL1, MYC, FZD7
                    hsa04210:Apoptosis                                                                                            0.0421      TNFRSF10A, PRKAR2A, EXOG, IKBKB, MAP3K14
                    hsa00562:Inositol phosphate metabolism                                                                        0.0477      MINPP1, TPI1, PIKFYVE, PIP5K1A
                    hsa05169:Epstein-Barr virus infection                                                                         0.00175     POLR3F, XPO1, HDAC4, GTF2E2, HDAC2, GSK3B, PSMD3, MAP3K14, IKBKB, MYC
                    hsa05166:HTLV-I infection                                                                                     0.0122      WNT5A, XPO1, E2F3, KAT2B, MAP3K3, GSK3B, MAP3K14, IKBKB, MYC, FZD7
                    hsa05205:Proteoglycans in cancer                                                                              0.0267      WNT5A, EIF4B, SDC1, TIAM1, ERBB3, MYC, FZD7, ITPR1

Clinical associations of lncRNAs, miRNAs and mRNAs in the ceRNA network
-----------------------------------------------------------------------

In the 138 miRNA-mRNA matched samples of TCGA data, 114 had OS and 82 had RFS information. Univariate Cox regression analysis in these 138 samples showed that 32 RNAs were significantly associated with OS, including 1 DEL (RUSC1-AS1), 2 DEMs (hsa-miR-16 and hsa-miR-10) and 29 DEGs (i.e., PAWR, SCG5, SPRY4, MICAL2, SNX21, TRAPPC10 and SLC39A14); while 25 RNAs were associated with RFS, including one DEL (LINC00324), three DEMs (hsa-miR-16, hsa-miR-10 and hsa-miR-7) and 21 DEGs (i.e., PRDM5, SCG5, SPRY4, MICAL2 and ZFP1) ([Table 3](#table-3){ref-type="table"}). The OS and RFS related ceRNA networks were extracted independently as shown in [Figs. 5A](#fig-5){ref-type="fig"} and [5B](#fig-5){ref-type="fig"}.

Subsequently, multivariate Cox regression showed TRAPPC10 and SLC39A14 were independent factors for OS; RRM2 was an independent factor for RFS ([Table 4](#table-4){ref-type="table"}). Although SOD2, SLC44A1 and THEM4 were also screened to be significant, their hazard ratios (HR) were not consistent with the expected according to their expression levels. Combined with the univariate results, we suggested TRAPPC10 and SLC39A14 related ceRNA axes (TMEM51-AS1-miR-106-TRAPPC10; RUSC1-AS1-miR-16-SLC39A14) may be especially important. The Kaplan--Meier curve of these lncRNAs, miRNAs and mRNAs were drawn. As expected, the low expression of miR-16 ([Fig. 5D](#fig-5){ref-type="fig"}) was associated with poor prognosis and the high expression of RUSC1-AS1 ([Fig. 5C](#fig-5){ref-type="fig"}), SLC39A14 ([Fig. 5E](#fig-5){ref-type="fig"}) and TRAPPC10 ([Fig. 6A](#fig-6){ref-type="fig"}) was associated with shorter OS.
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###### Prognosis related lncRNAs, miRNAs and mRNAs in ceRNA network.
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  Overall survival   Recurrence free survival                                                   
  ------------------ -------------------------- ------- --------- -------- ------------ ------- ---------
  miRNA              hsa-miR-16                 0.506   0.00048   miRNA    hsa-miR-10   0.678   0.0135
                     hsa-miR-10                 0.653   0.016              hsa-miR-16   0.523   0.00355
  lncRNA             RUSC1-AS1                  1.09    0.01               hsa-miR-7    1.75    0.011
  mRNA               ADAM10                     2.01    0.0435    lncRNA   LINC00324    1.38    0.0205
                     AHCYL2                     0.739   0.0315    mRNA     AFF4         2.43    0.036
                     CNPY3                      0.602   0.048              CELSR2       0.576   0.041
                     DLC1                       1.56    0.025              ERBB3        0.392   0.041
                     E2F3                       0.661   0.0355             LRRC8E       0.577   0.029
                     FUS                        0.531   0.0345             MAP4K4       2.12    0.0475
                     HPN                        0.878   0.036              MICAL2       1.76    0.0115
                     ITPR1                      2.19    0.036              NXPH4        0.702   0.0265
                     LRRC40                     2.56    0.042              PCYOX1       0.484   0.0445
                     MICAL2                     1.49    0.0325             PRDM5        1.64    0.0135
                     NXPH4                      0.722   0.032              PTBP1        8.8     0.047
                     PAWR                       1.57    0.037              PTPN1        3.26    0.038
                     PRPSAP2                    0.563   0.045              PYGO2        0.252   0.036
                     PTPN12                     2.19    0.0485             RRM2         2.32    0.043
                     PUS1                       0.668   0.0385             SCG5         1.84    0.00065
                     PYGO2                      0.334   0.0485             SDC1         0.459   0.042
                     RAB10                      1.59    0.0295             SLC39A14     1.85    0.042
                     SAR1B                      1.62    0.039              SLC44A1      0.445   0.011
                     SCG5                       1.4     0.0295             SPRY4        2.28    0.007
                     SLC39A14                   1.78    0.027              ST3GAL2      2.34    0.033
                     SNX21                      0.502   0.048              THEM4        0.278   0.006
                     SOD2                       0.736   0.038              ZFP1         3.35    0.032
                     SPRY4                      1.98    0.023                                   
                     ST3GAL2                    1.87    0.0345                                  
                     TAP2                       0.68    0.0425                                  
                     TCFL5                      0.613   0.033                                   
                     TRAPPC10                   0.324   0.037                                   
                     TSC22D2                    1.36    0.0295                                  
                     TSEN15                     1.58    0.0415                                  

![Prognosis related competing endogenous RNAs (ceRNAs) interaction axes.\
(A) lncRNA-miRNA-mRNA network for overall survival; (B) lncRNA-miRNA-mRNA network for recurrence free survival. Square nodes represent lncRNAs; triangle nodes represent miRNAs; round nodes represent mRNAs. Edges represent the possible associations between lncRNAs, miRNAs and mRNAs. Red, upregulated; green, downregulated.; Kaplan--Meier analysis of the lncRNA (C), miRNA (D) and mRNA (E) of crucial ceRNA axis in which all lncRNA, miRNA and mRNA were prognosis-related and mRNA was an independent prognostic factor.](peerj-07-7456-g005){#fig-5}
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###### Independent prognostic factors for LSCC by multivariate Cox regression.
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  OS             RFS                                                                                          
  -------------- ------------ -------- ---------- --------- -------------- ------------ ---------- ---------- ----------
  TRAPPC10       **0.0106**   0.0941   0.01535    0.5768    SLC44A1        **0.0055**   0.1719     0.0496     0.5958
  Alcohol        **0.0252**   0.0391   0.00229    0.668     THEM4          **0.0101**   0.2215     0.07023    0.6988
  SLC39A14       **0.0289**   9.37     1.26       69.8      RRM2           **0.0151**   34.8562    1.99009    610.503
  SOD2           **0.0456**   2.748    1.01992    7.4038    Age            0.0875       0.06502    0.00283    1.494
  SCG5           0.0515       8.6      0.986      75.1      T              0.1882       0.09721    0.00302    3.129
  Grade          0.0536       0.0053   0.000025   1.09      Stage          0.1883       14.2194    0.27247    742.056
  MICAL2         0.0872       0.141    0.0149     1.33      ZFP1           0.2108       3.5709     0.48649    26.2105
  RUSC1-AS1      0.0894       1.1434   0.97957    1.3347    LINC00324      0.2134       1.5429     0.77921    3.0549
  Gender         0.1057       0.002    1.08E−06   3.72      PCYOX1         0.2206       0.16586    0.009362   2.939
  CNPY3          0.1069       43.1     0.444      4170      CELSR2         0.2233       0.12475    0.004376   3.556
  PUS1           0.1534       0.0927   0.00354    2.43      NXPH4          0.2429       0.58688    0.239935   1.435
  HPN            0.1538       0.398    0.112      1.41      Gender         0.2507       0.11327    0.002754   4.658
  hsa-mir-16-2   0.1626       0.5574   0.24539    1.266     PTPN1          0.2567       17.1232    0.126445   2318.83
  Age            0.1641       0.0323   0.000256   4.07      AFF4           0.3093       17.52882   0.070156   4379.665
  PTPN12         0.204        42.7     0.13       14000     PYGO2          0.3218       0.06118    0.000243   15.379
  ADAM10         0.245        0.136    0.00472    3.93      SLC39A14       0.3303       1.5919     0.62436    4.0587
  LRRC40         0.2467       0.0333   0.000106   10.5      SPRY4          0.3574       1.6716     0.55973    4.9922
  Stage          0.2589       185      0.0215     158000    Grade          0.4953       0.24206    0.004104   14.277
  RAB10          0.2779       0.0066   7.71E-07   57.1      MAP4K4         0.4973       0.21996    0.002775   17.436
  T              0.2814       0.0214   0.000020   23.3      hsa-mir-16-2   0.50105      0.7001     0.24778    1.978
  TSC22D2        0.3088       1.7322   0.60129    4.99      ERBB3          0.6193       2.56113    0.06268    104.645
  FUS            0.3262       0.0128   2.11E-06   77.1      PTBP1          0.629        8.46884    0.00146    49149.03
  DLC1           0.3279       0.168    0.00472    5.99      tobacco        0.6901       0.59073    0.04442    7.856
  PRPSAP2        0.328        0.0598   0.000212   16.9      SCG5           0.7040       1.2036     0.46263    3.1314
  TSEN15         0.3295       2.1853   0.45397    10.5197   PRDM5          0.7108       1.45392    0.20106    10.514
  ST3GAL2        0.3643       1.4916   0.62882    3.5381    N              0.7903       0.69963    0.05030    9.731
  PYGO2          0.4608       6.86     0.0412     1140      LRRC8E         0.7914       0.70897    0.05545    9.065
  E2F3           0.4736       2.69     0.18       40.2      MICAL2         0.8244       1.2676     0.15616    10.289
  N              0.5037       0.203    0.00188    21.8      SDC1           0.8476       1.1355     0.31079    4.1489
  SPRY4          0.5551       1.3026   0.54132    3.1346    hsa-mir-7-2    0.8556       1.1305     0.30175    4.2351
  TAP2           0.574        0.7112   0.21679    2.3332    hsa-mir-10a    0.9186       0.9692     0.53189    1.7661
  NXPH4          0.6486       0.784    0.276      2.23      ST3GAL2        0.9385       0.9482     0.24524    3.666
  TCFL5          0.6954       0.7436   0.16866    3.278     Alcohol        0.9937       1.01803    0.01187    87.316
  Tobacco        0.717        1.67     0.105      26.5                                                        
  SNX21          0.8253       0.8703   0.25359    2.9871                                                      
  hsa-mir-10a    0.8392       0.9451   0.54739    1.6316                                                      
  PAWR           0.842        1.7      0.00918    315                                                         
  SAR1B          0.9106       1.25     0.0244     64.3                                                        
  ITPR1          0.9121       1.19     0.0539     26.3                                                        
  AHCYL2         0.9767       1.06     0.0236     47.5                                                        

**Notes.**

*P*-value \< 0.05 shown in bold.

Furthermore, OS- and RFS-related DELs, DEMs and DEGs were also analyzed to investigate their associations with other clinical characteristics of LSCC to further confirm their importance. The results showed that RUSC1-AS1 was significantly associated with Pathologic N; OS- and RFS-related SPRY4 was associated with Pathologic M; OS-related MICAL2 was associated with Pathologic N and Pathologic stage; RFS-related ZFP1 and SLC39A14 were associated with Pathologic N; OS-related SNX21 and RFS-related SCG5 were associated with gender ([Table 5](#table-5){ref-type="table"}). These findings implied SPRY4, MICAL2, ZFP1, SNX21 and SCG5 related ceRNAs (LINC00324/RUSC1-AS1-miR-16-SPRY4/MICAL2, RUSC1-AS1-miR-7-ZFP1, TMEM51-AS1-miR-106-SNX21, RUSC1-AS1-miR-10-SCG5) were also crucial for LSCC. The Kaplan--Meier curve of SNX21 is shown in [Fig. 6B](#fig-6){ref-type="fig"} and the other DEGs are displayed in [Figs. S1](#supp-10){ref-type="supplementary-material"} and [S2](#supp-11){ref-type="supplementary-material"}.

Discussion
==========

Although epigenetics modification has been shown to trigger silencing or overexpression of lncRNAs in cancer ([@ref-12]; [@ref-17]; [@ref-64]), the aberrant methylation-mediated expression changes of lncRNAs remain unclear in LSCC. We, for the first time, found that the downregulation of lncRNA TMEM51-AS1 may be mediated by hyper-methylation. Few studies investigated the roles of TMEM51-AS1 in cancer except one study indicated downregulated TMEM51-AS1 was significantly correlated with poor OS in chromophobe renal cell carcinoma ([@ref-18]). In the present study, we predicted that TMEM51-AS1 might function as a ceRNA to regulate SNX21 and TRAPPC10 through sponging miR-106b. Evidence demonstrated that miR-106b was up-regulated in LSCC ([@ref-34]; [@ref-59]), which was also confirmed in our microarray study. miR-106b was reported to promote the proliferation and invasion of LSCC cells by targeting RUNX3 ([@ref-60]), while induce cell cycle G0/G1 arrest by inhibiting tumor suppressor RB ([@ref-5]). Although no study revealed the roles of SNX21 in cancer, its family genes, such as SNX1 ([@ref-61]), SNX5 ([@ref-24]) and SNX9 ([@ref-2]) were suggested to be tumor suppressor related. Therefore, SNX21 may be theoretically downregulated in LSCC by miR-106b. Consistent with this hypothesis, our study showed that SNX21 was less expressed in LSCC tissues and patients with high expression of SNX21 had a higher OS rate. There was only one study to suggest the roles of TRAPPC10 until now and showed TRAPPC10 was an oncogenic driver to predict the poor prognosis for breast cancer patients ([@ref-41]), which seemed to be contrast with our results, implying TRAPPC10 may be a new tumor suppressor gene for LSCC. The tumor inhibition effects of TRAPPC10 may be related to its potential to activate GTPase RAB11 ([@ref-36]) and the Rab coupling protein, the targeted deletion of which led to accelerated tumor onset ([@ref-4]).

![Kaplan--Meier curve of lncRNA TMEM51-AS1 ceRNA related mRNAs.\
(A) TRAPPC10, which was an independent prognostic factor; (B) SNX21, which was overall survival related in univariate Cox regression analysis.](peerj-07-7456-g006){#fig-6}
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###### Clinical characteristics related to lncRNAs, miRNAs and mRNAs in prognostic ceRNA network.
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  Clinical characteristics            **Significant related**        
  ----------------------------------- ------------------------- ---- -----------------------------------------------------------------------
  Age( ≥60/\<60 y)                    --                        --   ADAM10, FUS, MICAL2, [LRRC8E]{.ul}
  Gender(Male/Female)                 --                        --   DLC1, HPN, PTPN12, SNX21, ST3GAL2, [LRRC8E, NXPH4, PTPN1, SCG5,]{.ul}
  Alcohol use(Yes/No)                 --                        --   CNPY3, PYGO2, SLC39A14, TAP2
  Pathologic_M(M0/-)                  --                        --   ADAM10, CNPY3, E2F3, **SPRY4**, [LRRC8E, MAP4K4, PTBP1, RRM2]{.ul}
  Pathologic_N(N0/N1/N2/N3/-)         RUSC1-AS1                 --   DLC1, FUS, MICAL2, SOD2, [PCYOX1, RRM2, SLC39A14, ZFP1]{.ul}
  Pathologic_T(T1/T2/T3/T4/-)         --                        --   LRRC40, PRPSAP2, SOD2, TSEN15, [CELSR2, PTPN1]{.ul}
  Pathologic_stage(I/II/III/IV/-)     --                        --   MICAL2, PRPSAP2, SPRY4, [CELSR2, MAP4K4, PCYOX1, PTPN1]{.ul}
  Grade(G1/G2/G3/G4)                  --                        \-   AHCYL2, DLC1 [, PCYOX1, PTPN1, RRM2]{.ul}
  Tobacco use(Reform/Current/Never)   --                        --   HPN, RAB10, SAR1B, SOD2, TAP2

**Notes.**

Underlined genes were recurrence free survival related; the other genes were overall survival related. Bolded genes was both recurrence free and overall survival related.

Furthermore, we identified several other ceRNA axes, although they were not methylation-related, including LINC00324/RUSC1-AS1-miR-16-SPRY4/MICAL2/ SLC39A14, RUSC1-AS1-miR-10-SCG5 and RUSC1-AS1-miR-7-ZFP1. All these lncRNAs, miRNAs and mRNAs were significantly associated with OS and/or RFS, indicating these ceRNA axes may also be underlying therapeutic targets.

Although related report was rare, RUSC1-AS1 ([@ref-22]) and LINC00324 ([@ref-37]) had been indicated to be highly expressed in cancer cells, which were similarly confirmed in LSCC samples. Accumulating evidence also has proved the roles of miR-16, miR-7 and miR-10 in various types of cancer. miR-16 could be downregulated in tissue samples and cell lines of lung cancer ([@ref-27]) and osteosarcoma ([@ref-23]). Ectopic expression of miR-16 inhibited cell proliferation, colony formation *in vivo* and, migration and invasion *in vitro* by regulating its target genes RAB23 and Smad3 ([@ref-23]; [@ref-63]). miR-10a was down-regulated in laryngeal epithelial premalignant lesions with increasing grade of dysplasia ([@ref-20]). Overexpression of miR-10a inhibited cell metastasis by regulating epithelial-to-mesenchymal transition (EMT) ([@ref-33]). miR-7-5p was lower expressed in brain-metastatic lesions of breast cancer ([@ref-19]) and the use of miR-7-5p mimics suppressed cell proliferation and induced apoptosis ([@ref-50]) via modulating the expression of Kruppel like factor 4. In agreement with these studies, we also found that these three miRNAs were less expressed (especially miR-10 and miR-7) in LSCC and negatively associated with OS and/or RFS. Although the downstream target genes of these miRNAs have been reported as above, their functions in LSCC remain poorly understood. We predicted that SPRY4/MICAL2/SLC39A14, SCG5 and ZFP1 may be the potential targets of miR-16, miR-10 and miR-7, respectively in LSCC, which had not been validated previously. Nevertheless, the studies on the molecular mechanisms of these DEGs may indirectly explain their potential interactions. The expression of SPRY4 was upregulated in testicular germ cell tumors ([@ref-54]). MICAL2 was a recently identified proto-oncogene, which increased cell proliferation to accelerate tumor growth, and promoted the expression of EMT-related proteins to increase cell metastasis ([@ref-35]; [@ref-56]). Immunohistochemical analysis showed the expression level of SLC39A14 was significantly higher in hepatocellular carcinoma tissues than that in adjacent tissues and negatively correlated with survival time ([@ref-14]). Also, the upregulation of SLC39A14 in tumor cells may be attributed to the loss of its interactive gene p53, a tumor suppressor ([@ref-66]). Although there were no studies to discuss the roles of SCG5 in cancer, its family members secretogranin II and III have been seen to be overexpressed in prostate cancer ([@ref-10]) and small cell lung carcinoma ([@ref-55]), suggesting SCG5 may also be oncogenic for LSCC. Zinc finger proteins had also been observed to promote cell growth and metastasis in nasopharyngeal carcinoma ([@ref-30]). In line with these findings, SPRY4, MICAL2, SLC39A14, SCG5 and ZFP1 were all upregulated in LSCC and associated with poor prognosis.

There were some limitations in this study. First, although all the known microarray or sequencing data from the public database had been included, the sample size was still not large which may influence the results. Therefore, additional clinical trials with larger samples may be essential to confirm their expression and prognosis. Second, we only preliminarily predicted that these ceRNA axes may be associated with LSCC development and prognosis. The regulatory relationships between lncRNAs and miRNAs as well as between miRNAs and mRNAs needed further experimental confirmation *in vitro* and *in vivo* (i.e., dual luciferase reporter assay or loss-of-function). Third, whether the expression of TMEM51-AS1 was regulated by methylation should be validated by using the methylation inhibitor 5-azacytidine. Fourth, although we have normalized the data from different platforms, this may still cause some underlying bias.

Conclusion
==========

Our present study identifies several important mechanisms for the development and progression of LSCC: (1) methylation-mediated upregulation of lncRNA TMEM51-AS1 may function as a ceRNA for miR-106b to regulate SNX21 and TRAPPC10; (2) survival-related RUSC1-AS1/LINC00324 may function as a ceRNA to sponge miR-16, miR-10 or miR-7 and then regulate SPRY4/ MICAL2/SLC39A14, SCG5/PRDM5 and ZFP1, respectively. Altogether, these lncRNA, miRNAs or mRNAs may be potential prognostic biomarkers and therapeutic targets of LSCC.
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